Rachel Batterham

Senior vice president of medical innovation and external engagement, Lilly Cardiometabolic Health

Appears in 1 story

Stories

Lilly's oral GLP-1 Foundayo clears cardiovascular safety bar in largest type 2 diabetes trial

Active

Millions with type 2 diabetes manage blood sugar with daily injections. Lilly's Foundayo is a pill that could replace them, and in its largest trial it matched insulin on heart safety while cutting weight and blood sugar more.

Updated 8 minutes ago